UK Flag
de flag
French Flag
Dutch Flag
  +44 20 7660 1406

Category: Glioblastoma: News, Information & Studies


Glioblastoma is a highly malignant and aggressive type of brain tumour that poses significant challenges in diagnosis and treatment. It is the most common form of primary brain cancer in adults and demands attention due to its aggressive nature and limited treatment options.

Unraveling Dendritic Cells in Glioblastoma Immunotherapy

Glioblastoma (GBM), a devastating primary brain cancer, remains a formidable challenge with a median survival of less than 15 months despite current standard treatments of surgery, radiation, and chemotherapy.
MGMT Methylated

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Clinical study on Malignant Astrocytoma

Dendritic Cell Vaccine trial for Malignant Astrocytoma: potential interaction with adjuvant Chemotherapy

PFS for Adult Patienbts

Postoperative Adjuvant Dendritic Cell Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

T-Cell obtained from CFS

Immune response generated with the administration of autologous Dendritic Cells pulsed with an allogenic Tumoral Cell- lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma

MRI Scan

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study


Glioblastoma: an aggressive type of brain cancer

Glioblastoma is an aggressive type of brain cancer that forms in the supportive tissue of the brain. Glioblastoma is a relatively rare form of cancer, accounting for about 3% of all brain and nervous system tumours. However, it is the most common and aggressive type of primary brain tumour, and it has a very poor prognosis with a five-year survival rate of only 5%.

The incidence of glioblastoma varies by region and population, but it is estimated to be around 3–4 cases per 100,000 people per year worldwide. It is more common in men than women, and it typically occurs in adults between the ages of 45 and 70.

Glioblastoma can be detected through a variety of methods, including imaging tests, neurological exams, and biopsies. Imaging tests, such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, are typically the first step in diagnosing glioblastoma. These tests can produce detailed images of the brain, allowing doctors to see if there are any abnormalities, such as a tumour. If an abnormality is detected, a neurological exam may be performed to assess the patient’s cognitive function, vision, and other neurological symptoms. This can help doctors determine the location and severity of the tumour.

A biopsy is often needed to definitively diagnose glioblastoma. In a biopsy, a small sample of the tumour is removed and examined under a microscope to determine if it is cancerous and, if so, what type of cancer it is. In some cases, a biopsy may not be possible, particularly if the tumour is located in a sensitive area of the brain. In these cases, doctors may rely on imaging tests and neurological exams to make a diagnosis and determine a treatment plan. Overall, early detection and diagnosis of glioblastoma are crucial for improving outcomes and increasing the chances of successful treatment.

The stages of glioblastoma are generally classified as either primary or secondary. Primary glioblastoma develops rapidly and has no known cause, while secondary glioblastoma develops from a lower-grade tumour and progresses more slowly.

Common treatments for glioblastoma include surgery, radiation therapy, and chemotherapy. Surgery involves the removal of as much of the tumour as possible, while radiation therapy and chemotherapy are used to kill any remaining cancer cells. Despite aggressive treatment, glioblastoma is difficult to cure, and the chances of recovery depend on the patient’s age, overall health, and the extent of the tumour at the time of diagnosis.

Immucuras Dendritic Cell Therapy is a promising new treatment for glioblastoma that involves activating the body’s immune system to fight cancer cells. Dendritic cells are specialized immune cells that can recognize and destroy cancer cells.

In fact, there are several articles like this one: Dendritic Cell Vaccination With Extension of Survival Among Patients With Glioblastoma, that discuss about Dendritic Cell Therapy for glioblastoma. The researchers found that Dendritic Cell Therapy, which is a form of immunotherapy, was more effective in treating glioblastoma compared to standard treatments such as chemotherapy or radiation. Dendritic cells are important for initiating an immune response against cancer cells, and the therapy involves extracting a patient’s own dendritic cells and activating them to recognize and attack the cancer cells. The study showed promising results, with patients who received dendritic cell therapy surviving longer and having better quality of life compared to those who received standard treatments.

In Dendritic Cell Therapy, the patient’s own dendritic cells are harvested and exposed to proteins found on glioblastoma cells. The activated dendritic cells are then infused back into the patient’s body, where they can activate other immune cells to recognize and destroy the cancer cells.

Studies have shown that Dendritic Cell Therapy can be effective in treating glioblastoma, particularly when used in combination with other treatments like surgery, radiation therapy, and chemotherapy. While more research is needed, dendritic cell therapy offers a promising new approach to treating this deadly cancer.

The following statement was provided by a family member of a patient who received treatment for brain cancer from the Immucura team:

This statement was given by a family member of the patient:
“Little Brooke was sick at the hospital and after her therapy with Immucura, they told us that her blood was A*, they said they have never seen blood results this good, it was on top levels.” Brooke.
You can check all the testimonials here: Immucura’s testimonials

Get In Touch